With selected patients glaucoma filtration surgery is highly successful. However, there is growing evidence that chronic topical medical therapy has a deleterious effect on surgical outcome. It has been suspected that topical drugs exert an adverse effect on the conjunctiva which results in altered postoperative wound healing. In this review the effect of previous topical antiglaucoma medication on the conjunctiva and the outcome of subsequent glaucoma filtration surgery are discussed.
With selected patients glaucoma filtration surgery is highly successful. However, there is growing evidence that chronic topical medical therapy has a deleterious effect on surgical outcome. It has been suspected that topical drugs exert an adverse effect on the conjunctiva which results in altered postoperative wound healing. In this review the effect of previous topical antiglaucoma medication on the conjunctiva and the outcome of subsequent glaucoma filtration surgery are discussed.
The effect of previous topical therapy on the results of glaucoma filtration surgery In a study aimed at identifying potential risk factors for failure of pressure control following glaucoma triple procedures (trabeculectomy, cataract extraction and intraocular lens implantation), the only significant adverse factor identified was cumulative years of preoperative topical therapy (number of medications x the treatment duration for each). ' The hazard ratio for this factor was 1 1 indicating that the risk of failure doubled after 8 years of cumulative therapy. The number of preoperative medications used was not isolated as a significant risk factor and the data were insufficient to identify any specific type of medication as the major risk factor.
In a similar study,2 previous treatment with multiple topical agents was reported to be associated with a lower trabeculectomy success rate in comparison with a group of patients undergoing primary trabeculectomy (Fig 1) . The largest single influence on the outcome of trabeculectomy alone was the number of preoperative antiglaucoma medications used (hazard ratio= 5) . This controlling for factors that may have been confounders for the effect of medication number, in particular the presenting intraocular pressure (IOP). Since it was probable that the higher the IOP, the greater the number of treatments used, a higher order interaction was suspected. The duration of topical treatment was also significant, but with a hazard ratio just below 1, a longer duration appeared to have a borderline protective effect. It was thus proposed that large numbers of medications used during a relatively short period may have a greater adverse effect than the same amount of treatment over a long period. Previous exposure to sympathomimetics was identified as a significant adverse factor and the patients whose trabeculectomies failed had used more adrenalinebased preparations than those whose trabeculectomies were successful (55% vs 26%). In contrast, previous exposure to timolol had no significant effect on the outcome of surgery. Previous exposure to pilocarpine was not identified as a significant adverse factor, but this may have been due to the fact that only 2% of the treated patients in this study had not received pilocarpine and its use was thus a very poor determinant of risk of failure.
Previous topical therapy has also been identified as an adverse factor for the outcome of trabeculectomy performed in children with congenital glaucoma.3 With failure defined as an IOP >21 mm Hg the adjusted risk ratio was 56, and when defined as the requirement of additional surgical or medical therapy it was 7-2. Analysis by multiple regression also showed that the effect of previous topical therapy was detrimental, reducing the quality of IOP control at 3, 6, and 12 months. The effects of treatment type, amount, or duration were not analysed.
Topical therapy with sympathomimetics has also been reported to increase the risk of failure secondary to the development of Tenon's capsule cysts with a relative risk of 1 9.4 Neither miotics nor fi blockers had a significant effect on the development of cysts but the effect of duration or amount of topical treatment was not addressed in this study and it is possible that the effect of sympathomimetics reflected these factors rather than one of treatment type. Theodore8 and Wilson9"' have reviewed the adverse external ocular effects ofa number oftopical drugs, including antiglaucomatous medication. It is clear that the conjunctiva is able to react in a number of ways in response to topical therapy (Table 1 ). It is probable that the development of pseudopemphigoid (drug-induced ocular cicatrisation) lies at the severe end of a spectrum of reactions, the other end of which is total tolerance (Fig 2) . On a clinical basis this concept is logical, for a full range of tolerance is seen in ophthalmic practice. Wright3' has shown that inferior forniceal shallowing due to subconjunctival fibrosis may be induced by sympathomimetic therapy. A recent study has further investigated this frequently subtle reaction to topical medication.32 A significant foreshortening of the inferior fornix was found with increasing age and, after taking this into account, after at least 3 years' exposure to topical antiglaucoma medications, irrespective oftype. The fact that different classes oftopically administered medications were associated with conjunctival shrinkage indicated that a common pathway may result in fibrosis.
SUBCLINICAL EFFECTS
In order to determine the effect of topical antiglaucoma medications on the cellular content on the conjunctiva, Sherwood from patients with glaucoma undergoing filtration surgery. The patients were divided into two groups. Primary trabeculectomy patients underwent trabeculectomy within a few weeks of their glaucoma diagnosis, following treatment with pilocarpine for a mean duration of only 3 weeks. Multitreatment patients underwent trabeculectomy after treatment with at least two different types of topical medication, for a minimum duration of 1 year (mean 7-7 years). In the epithelium, the multi-treatment conjunctiva showed a significant decrease in the number of goblet cells and increase in the number of cysts and non-epithelial cells such as lymphocytes or macrophages. A significant increase in the number of fibroblasts, macrophages, lymphocytes, and mast cells was found in both conjunctival substantia propria and Tenon's capsule (Fig 7) . The authors proposed that the increased number of fibroblasts and inflammatory cells in conjunctiva exposed to topical medications might enhance the risk of bleb failure after trabeculectomy. This study is of both interest and importance but did not identify whether any specific antiglaucoma medication was responsible.
In order to identify specific drugs responsible for such changes, Smith et al34 investigated the effect of antiglaucoma medications on the conjunctiva of rabbits, divided into four groups. Timolol, pilocarpine, adrenaline, or a combination of all three drugs were placed in one eye, twice daily, for 7 months. The fellow eye received distilled water and acted as a control. Analysis of the number of inflammatory cells, fibroblasts, and goblet cells revealed no statistically significant difference in number of any cell type between the control and treatment groups. However, as the authors point out the small number of eyes in each treatment group and the high variability in cell counts between each eye limited the power of such an analysis. A number of other reasons to explain the difference between these results and those of Sherwood et al were discussed. Firstly, the mean durations of topical therapy were significantly different, 7 months rather Steuhl et all proposed that intracellular changes such as vacuolisation and dilatation of the rough endoplasmic reticulum of surface epithelial cells may be attributable to the action of preservative (benzalkonium chloride). Since these changes were greatest with I blocker medications it was proposed that the cytotoxic action of the preservative was intensified by the simultaneous application of P blockers because of their destabilising effect on the tear film.
In contrast, Quaranta et al47 reported no evidence of pathological alterations to the conjunctiva after long term (6-10 years) therapy with timolol, although only four patients were compared with four controls. A similar conclusion was reached by Hoffman48 who reported that timolol placed in rabbit eyes for 1 year or beagle eyes for 2 years had no histomorphological effect on the conjunctiva.
The effect of pilocarpine on the density of goblet cells has been investigated by Gerstenberger and Marquardt who also demonstrated a circadian rhythm in goblet cell number.49
Long term use of pilocarpine (up to 20 years) was found to be associated with an increase in goblet cell number and it was proposed that this increase occurred secondary to maximal parasympathomimetic stimulation of the goblet cells. An The results of all these studies27"34549 contrast with the findings of Steuhl et al46 who reported that pilocarpine had a minimal effect on conjunctival cell differentiation.
Brandt et al5' used conjunctival impression cytology to assess the effect of topical antiglaucoma medication on the degree of epithelial metaplasia. Impression cytology specimens from patients on a stable regimen of up to three topical medications, for a minimum duration of 3 months, were compared with those from glaucoma suspects unexposed to topical medication. The control group had the lowest cumulative metaplasia score, consistent with healthy conjunctiva. The degree of metaplasia of three treatment groups ((3 blocker alone, blocker with pilocarpine, and blocker with pilocarpine and sympathomimetic) was significantly increased in comparison with the control group (Fig 8) 
